




>>Entry Name: Ranitidine, BAN, INN, JAN, USAN

Synonym(s): *N*-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-*N'*-methyl-2-nitro-1,1-ethenediamine, 9Cl



CAS Registry Number: 66357-35-5

Molecular Formula: C₁₃H₂₂N₄O₃S

Molecular Weight: 314.408

Accurate Mass: 314.141261

Percentage Composition: C 49.66%; H 7.05%; N 17.82%; O 15.27%; S 10.20%

Biological Use/Importance: Histamine H₂-receptor antagonist. Antiulcer agent, low toxicity

Development Status: Marketed drug. Worldwide 50th best selling prescription drug (as Zantac) (\$0.87 bn) (GlaxoSmithKline) (2000, Pharma Business)

Melting Point: Mp 69-70°

Calculated Log P Data: Log P 1.33 (uncertain value) (calc)

Sigma: R0633

>>Derivative: Hydrochloride

Synonym(s): Ranitidine hydrochloride, JAN, USAN. Azantac. Melfax. Noctone[‡]. Ranaps. Raniben. Ranidil. Raniplex. Rantec. Sostril. Taural. Terposen. Trigger. Ultidine. Zaedoc. Zantac. Zantidon. AH 19065. Many other names

CAS Registry Number: 71130-06-8

Extra CAS Registry Numbers(s): 66357-59-3

Melting Point: Mp 133-134°

>>Derivative: Compd. with bismuth citrate (1:1)

Synonym(s): Ranitidine bismuth citrate, BAN, USAN. Ranitidine bismutrex. Elicodil. Helirad. Pylorid. Pylorisin. Tritec. GR 122311X

CAS Registry Number: 128345-62-0

Molecular Formula: C₁₉H₂₇BiN₄O₁₀S

Molecular Weight: 712.489

Accurate Mass: 712.125165

Percentage Composition: C 32.03%; H 3.82%; Bi 29.33%; N 7.86%; O 22.46%; S 4.50%

Biological Use/Importance: Used in the eradication of *Helicobacter pylori*

Physical Description: No phys. props. reported

Development Status: Launched 1995

References:

- Ger. Pat.*, 1978, *Allen and Hanburys*, 2 734 070; *CA*, **88**, 190580b, (*synth, pharmacol*)
Daly, M.J. *et al.*, *Br. J. Pharmacol.*, 1981, **72**, 49; 55, (*pharmacol*)
Kojic-Prodic, B. *et al.*, *Acta Cryst. B*, 1982, **38**, 1837, (*cryst struct*)
Riley, A.J. *et al.*, *Curr. Clin. Pract. Ser.*, (Eds.), No. 1: *Ranitidine*, Excerpta Medica, Amsterdam, 1982, (*book*)
Brogden, R.N. *et al.*, *Drugs*, 1982, **24**, 267, (*rev, pharmacol*)
Gaginella, T.S. *et al.*, *Drug Intell. Clin. Pharm.*, 1983, **17**, 873, (*rev, pharmacol*)
Daly, M.J. *et al.*, *Prog. Med. Chem.*, 1983, **20**, 337, (*rev, pharmacol*)
Misiewicz, J.J. *et al.*, *Curr. Clin. Pract. Ser.*, 1984, **15**, (*book*)
Cholerton, T.J. *et al.*, *J.C.S. Perkin 2*, 1984, 1761, (*uv, ir, pmr, struct*)
Hohnjec, M. *et al.*, *Anal. Profiles Drug Subst.*, 1986, **15**, 533, (*rev, synth, anal, metab*)
Gerald, C.F. *et al.*, *Magn. Reson. Chem.*, 1987, **25**, 203, (*pmr, cmr*)
Negwer, M., *Organic-Chemical Drugs and their Synonyms*, 6th edn., Akademie-Verlag, 1987, 2946
Kirch, W., *Pharmacol. Ther.*, 1987, **33**, 129, (*rev*)
Grant, S.M. *et al.*, *Drugs*, 1989, **37**, 801, (*pharmacol, rev*)
Spurling, N.W. *et al.*, *Hum. Toxicol.*, 1989, **8**, 23, (*chronic tox*)
The Landmark Papers: The H₂-Receptor Antagonists, (Ed. Pounder, R.E.), Science Press, 1990, (*pharmacol, book*)
U.K. Pat., 1990, *Glaxo*, 2 220 937; *CA*, **113**, 65266n, (*Ranitidine bismutrex*)
Stables, R. *et al.*, *Aliment. Pharmacol. Ther.*, 1993, **7**, 237, (*Ranitidine bismutrex, pharmacol*)
Bradshaw, J., *Chron. Drug Discovery*, 1993, **3**, 45, (*rev*)
Wormsley, K.G., *Drugs*, 1993, **46**, 976, (*tox, rev*)
Bardhan, K.D. *et al.*, *Aliment. Pharmacol. Ther.*, 1995, **9**, 497, (*Ranitidine bismutrex*)
Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 1209; 1211
Lewis, R.J., *Sax's Dangerous Properties of Industrial Materials*, 8th edn., Van Nostrand Reinhold, 1992, RBF400